Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3CNS 1

Conditions

Sarcoma, Ewing 2Osteosarcoma 2Rhabdoid Tumor 1Osteosarcoma Recurrent 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Specimen Handling 288Magnetic Resonance Spectroscopy 238pembrolizumab 228Carboplatin 187Cisplatin 153Biopsy 151Cyclophosphamide 144Paclitaxel 133Nivolumab 123Gemcitabine 113Bevacizumab 106Radiotherapy 96Dexamethasone 86Pemetrexed 83fludarabine 78Fluorouracil 76Doxorubicin 76Docetaxel 76atezolizumab 73Radiation 72Leucovorin 70Rituximab 68Oxaliplatin 66venetoclax 61durvalumab 61Prednisone 61Vincristine 56Cetuximab 56Lenalidomide 55Etoposide 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Eflornithine × 30 days × Clear all
NCT06465199 2026-06-03

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
289 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Neuroblastoma, Sarcoma, Ewing, Osteosarcoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor

NCT07321912 2026-05-26

Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

Milton S. Hershey Medical Center

Phase 2 Recruiting
406 enrolled
Sarcoma

Sarcoma, Ewing, Osteosarcoma

NCT06892678 2026-05-14

DFMO

Montefiore Medical Center

Phase 1/2 Recruiting
15 enrolled
Sarcoma

Osteosarcoma Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡